Program
Etoricoxib
Also written as “etoricoxib”, “MK0663, etoricoxib” and “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”.
Its studies are mostly in Osteoarthritis · Pain · Low Back Pain · Acute Pain · Dysmenorrhea, led by 7 companies.
Drug pageEtoricoxib: every studyMany companies study it; this page follows only the 34 they lead. All 71 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 230 open or running | phase 4since Aug 25, 2004 | Aug 25, 2004 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 61 open or running | phase 3since Jul 13, 2021 | Jul 13, 2021 | Dec 31, 2026phase 3 · NCT06863701 |
| Analgesic Solutionsits history only | 10 open or running | phase 4since Dec 20, 2010 | Dec 20, 2010 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Jan 30, 2018 | Jan 30, 2018 | none ahead |
| Laboratorios Liomontits history only | 10 open or running | phase 3since Apr 15, 2026 | Apr 15, 2026 | none ahead |
| Pharmtechnologyits history only | 10 open or running | phase 1since Mar 31, 2021 | Mar 31, 2021 | none ahead |
| X-pert Medits history only | 10 open or running | phase 1since Jan 5, 2011 | Jan 5, 2011 | none ahead |
Also a collaborator on its studies: EPIC Research CRO, PT Equilab International and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Aug 25, 2004.
- Dec 20, 2010Analgesic Solutions’ first study: phase 4 study in Neuralgia, PostherpeticNew to Analgesic SolutionsAnalgesic Solutions · NCT01264237 · 120 enrolled · United Kingdom
- Jan 5, 2011X-pert Med’s first study: phase 1 study in MyalgiaNew to X-pert MedX-pert Med · NCT01271348 · 50 enrolled · Germany
- Sep 2, 2011Phase 4 study in OsteoarthritisOrganon · NCT01429168
- Oct 27, 2011Phase 3 study in DysmenorrheaOrganon · NCT01462370 · 139 enrolled
- Mar 12, 2012Phase 3 study in Osteoarthritis, KneeOrganon · NCT01554163 · 239 enrolled
- Nov 5, 2013Phase 2 study in Osteoarthritis PainOrganon · NCT01980940 · 70 enrolled
- Jan 30, 2018Dexa Medica Group’s first study: no phase study in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT03422575 · 26 enrolled · Indonesia
- Mar 31, 2021Pharmtechnology’s first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT04830579 · 34 enrolled · Russian Federation
- Jul 13, 2021Laboratorios Silanes S.A. de C.V.’s first study: phase 3 study in Back PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT04968158 · 124 enrolled · Mexico
- Sep 6, 2022Phase 1 study in PainLaboratorios Silanes S.A. de C.V. · NCT05533073 · 42 enrolled · Mexico
- Jul 18, 2024Phase 3 study in Acute PainLaboratorios Silanes S.A. de C.V. · NCT06517823 · 190 enrolled · Mexico
- Mar 3, 20252 phase 3 studiesLaboratorios Silanes S.A. de C.V. · NCT06863701, NCT06863662
- Dec 28, 2025Phase 3 study in BursitisLaboratorios Silanes S.A. de C.V. · NCT07328022 · 89 enrolled · Mexico
- Apr 15, 2026Laboratorios Liomont’s first study: phase 3 study in AgnosiaNew to Laboratorios LiomontLaboratorios Liomont · NCT07549386 · 123 enrolled · Mexico
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Arthritis, GoutyLaboratorios Silanes S.A. de C.V. · NCT06863701
TargetBeta
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule
Other programs on PTGS2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| Celecoxibrule | Viatris | phase 4 | 78 |
| Meloxicamrule | Boehringer Ingelheim | phase 4 | 67 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07549386Agnosia · Mexico | 3 | Completed | Laboratorios Liomont | Mar 27, 2025 | 123 |
| NCT07328022Bursitis · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Aug 20, 2025 | 89 |
| NCT06863701Arthritis, Gouty · Mexico | 3 | Recruiting | Laboratorios Silanes S.A. de C.V. | Dec 31, 2026 | 72 |
| NCT06863662Spasm · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Sep 26, 2025 | 136 |
| NCT06517823Acute Pain · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Oct 4, 2024 | 190 |
| NCT05533073Pain · Mexico | 1 | Completed | Laboratorios Silanes S.A. de C.V. | Sep 7, 2020 | 42 |
| NCT04968158Back Pain · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Mar 15, 2022 | 124 |
| NCT04830579Bioequivalence · Russian Federation | 1 | UNKNOWN | Pharmtechnology | Apr 28, 2021 | 34 |
| NCT03422575Healthy · Indonesia | – | Completed | Dexa Medica Group | Dec 2015 | 26 |
| NCT01980940Osteoarthritis Pain | 2 | Completed | Organon | Nov 26, 2014 | 70 |
| NCT01554163Osteoarthritis, Knee | 3 | Completed | Organon | Mar 2013 | 239 |
| NCT01462370Dysmenorrhea | 3 | Completed | Organon | Jun 2012 | 139 |
| NCT01429168Osteoarthritis | 4 | Withdrawn | Organon | Aug 2012 | 0 |
| NCT01271348Myalgia · Germany | 1 | Completed | X-pert Med | Oct 2011 | 50 |
| NCT01264237Neuralgia, Postherpetic · United Kingdom | 4 | UNKNOWN | Analgesic Solutions | Aug 2011 | 120 |
| NCT01208207Spondylitis, Ankylosing | 3 | Completed | Organon | Nov 12, 2014 | 1,015 |
| NCT01208181Arthritis, Rheumatoid | 3 | Completed | Organon | Jun 9, 2014 | 1,404 |
| NCT00820027Pain, Postoperative | 3 | Completed | Organon | Dec 13, 2010 | 776 |
| NCT00788710Acute Pain Following a Total Abdominal Hysterectomy | 3 | Completed | Organon | Jul 2010 | 430 |
| NCT00757627Pain | 4 | Completed | Organon | Dec 2008 | 500 |
| NCT00694369Postoperative Dental Pain | 3 | Completed | Organon | Dec 2008 | 588 |
| NCT00393354Low Back Pain | 3 | Completed | Organon | Nov 2000 | 325 |
| NCT00393211Low Back Pain | 3 | Completed | Organon | Nov 2000 | 319 |
| NCT00380627Pain | 4 | Completed | Organon | Jan 31, 2006 | 337 |
| NCT00380523Pain | 4 | Completed | Organon | May 2005 | 237 |
| NCT00269191Osteoarthritis | 3 | Completed | Organon | Nov 7, 2003 | 528 |
| NCT00264147Arthritis, Rheumatoid | 2 | Completed | Organon | Mar 2008 | 761 |
| NCT00242489Osteoarthritis | 2 | Completed | Organon | Feb 1999 | 1,167 |
| NCT00095017Bone Neoplasms | 2 | Withdrawn | Organon | 0 | |
| NCT00092781Osteoarthritis | 3 | Completed | Organon | Feb 1, 2005 | 500 |
| NCT00092768Osteoarthritis | 3 | Completed | Organon | Feb 1, 2005 | 500 |
| NCT00092755Osteoarthritis | 3 | Completed | Organon | Nov 13, 2003 | 548 |
| NCT00092729Dysmenorrhea | 3 | Completed | Organon | Dec 6, 2002 | 129 |
| NCT00090181Chronic Low Back Pain | 4 | Completed | Organon | Mar 2005 | 401 |
How it is read
Names in the registry
- “etoricoxib”, 7 entries
- “Etoricoxib”, 4 entries
- “MK0663, etoricoxib”, 3 entries
- “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”, 2 entries
- “Etoricoxib 90 mg”, 2 entries
Codes read as this program: MK0663.
Conditions, from the studies’ own filings
- Osteoarthritis, 8 studies
- Pain, 5 studies
- Low Back Pain, 3 studies
- Acute Pain, 2 studies
- Dysmenorrhea, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.